OSE Immunotherapeutics SA
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 6OP.F | HBP.TO | OSTX | ATORX.ST | CHRS | ACTI.ST | |
|---|---|---|---|---|---|---|
| Market cap | 42.99M | 70.27M | 53.83M | 38.18M | 131.36M | 100.96M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -8.4 | 3.3 | -0.1 | -1.3 | — |
| Price/book | 1.4 | 4.8 | -4.4 | 0.3 | 2.2 | 2.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −66.91% | −54.68% | −36.81% | −99.44% | −42.95% | −42.74% |
| Today | −2.85% | 0.00% | −0.86% | 0.00% | +5.54% | +4.08% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 6OP.F news ›OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedica... OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of…
OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026
NANTES, France, August 28, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the 'Company'), today announced that th... OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2,…
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Tr
OSE Immunotherapeutics' Tedopi Combination Meets Primary Endpoint In NSCLC Trial
OSE Immunotherapeutics SA (OSE), a clinical-stage biotech company, announced topline results from the Combi-TED academic Phase 2 international clinical trial of Tedopi sponsored by FoRT and evaluating Tedopi (OSE2101), in combination with…
OSE Immunotherapeutics: first patient treated in a Phase 2 study
The biotech company welcomed the announcement by its partner Veloxis Pharmaceuticals, Inc. regarding the treatment of the first patient enrolled in the Phase 2 RENGEVITY-201 clinical trial. The study aims to evaluate Pegrizeprument (also…
Transcript : OSE Immunotherapeutics SA - Special Call
Presenter SpeechMarc Le Bozec Hello, everyone. My name is Marc Le Bozec. I'm the CEO of OSE Immunotherapeutics, which is a listed company on Paris Stock Market. We're very happy and very proud to... Transcript : OSE Immunotherapeutics SA -…
OSE Immunotherapeutics Recovers Following Oddo BHF Endorsement
OSE Immunotherapeutics is trading in the green on the Paris Stock Exchange, potentially snapping a four-session losing streak that saw the stock shed 6.59%.... The biotechnology firm is benefiting from bargain hunting as well as a positive…
OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference
Nantes, France, October 15, 2026 - 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation,…
OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant...
Nantes, France, September 9, 2026 – 6pm CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE
OSE Immunotherapeutics SA Auditor Raises 'Going Concern' Doubt
OSE Immunotherapeutics SA filed its Annual on Jun 05, 2026 for the period ending Dec 31, 2025. In this report its auditor, Nexbonis Advisory, Ernst & Young et Autres, gave an unqualified opinion... Biotechnology & Medical Research OSE…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com8
- markets.businessinsider.com5
- manilatimes.net1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.